No black box warning on record for Alecensa

As of the latest FDA labeling reviewed, Alecensa (ALECTINIB HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Alecensa medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Monitor liver laboratory tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. In case of severe ALT, AST, or bilirubin elevations, withhold, then reduce dose, or permanently discontinue ALECENSA. ( 2.4 , 5.1 ) Int

No black box warning on record for Alecensa

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Monitor liver laboratory tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. In case of severe ALT, AST, or bilirubin elevations, withhold, then reduce dose, or permanently discontinue ALECENSA. ( 2.4 , 5.1 ) Int

Alecensa Black Box Warning

No black box warning on record for Alecensa

Other warnings & precautions

Alecensa Black Box Warning

No black box warning on record for Alecensa

Other warnings & precautions